Healthcare [ 6/11 ] | Biotechnology [ 76/148 ]
CH | NYSE | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 23 | 0.58 Increased by +169.05% | 0.44 Increased by +31.82% |
| May 9, 23 | -0.74 Decreased by -236.36% | -0.80 Increased by +7.50% |
| Feb 28, 23 | -0.30 Increased by +33.33% | -0.29 Decreased by -3.45% |
| Nov 8, 22 | -0.65 Increased by +30.11% | -0.35 Decreased by -85.71% |
| Aug 9, 22 | -0.84 Increased by +12.50% | -0.91 Increased by +7.69% |
| May 9, 22 | -0.22 Increased by +52.17% | -0.70 Increased by +68.57% |
| Mar 3, 22 | -0.45 Increased by +57.14% | -0.86 Increased by +47.67% |
| Nov 2, 21 | -0.93 Decreased by -20.78% | -0.92 Decreased by -1.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 19.28 M Decreased by -74.73% | -47.12 M Increased by +6.90% | Decreased by -244.34% Decreased by -268.49% |
| Mar 31, 23 | 18.99 M Increased by +9.84% | -59.43 M Increased by +7.69% | Decreased by -312.90% Increased by +15.95% |
| Feb 28, 23 | 19.80 K Decreased by -99.96% | 0.00 Increased by +100.00% | Increased by 0.00% Increased by +100.00% |
| Dec 31, 22 | 69.80 M Increased by +310.34% | -24.16 M Increased by +29.74% | Decreased by -34.61% Increased by +82.88% |
| Sep 30, 22 | 76.32 M Increased by +480.52% | -50.61 M Increased by +29.27% | Decreased by -66.31% Increased by +87.82% |
| Jun 30, 22 | 17.29 M Increased by +359.87% | -64.37 M Increased by +11.29% | Decreased by -372.30% Increased by +80.71% |
| Mar 31, 22 | 46.50 M Increased by +N/A% | -16.66 M Increased by +67.67% | Decreased by -35.83% Decreased by N/A% |
| Dec 31, 21 | 17.01 M Increased by +N/A% | -34.38 M Increased by +38.53% | Decreased by -202.12% Decreased by N/A% |
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.